Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

J Cancer 2021; 12(19):5879-5887. doi:10.7150/jca.55181 This issue Cite

Research Paper

LncRNA-PANDAR regulates the progression of thyroid carcinoma by targeting miR-637/KLK4

Yi Qing1, Qian Li2, Ling-Yan Zhao3, Ping Shi3, Jin-Lu Shan2✉, Wei Zhang4✉

1. Department of Oncology, Affiliated Hospital of Chengdu University, Chengdu 610081, People's Republic of China.
2. Department of Oncology, Daping hospital, Army Medical University, Chongqing, 400042, China.
3. Department of respiratory and critical care medicine, Guangyuan Central Hospital, Guangyuan City, Sichuan Province, 628000, China.
4. Department of medical oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Centre, School of Medicine, University of Electronic Science and Technology of China, Chengdu, 610041, China.

✉ Corresponding authors: Wei Zhang, Department of medical oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, 610041, China. E-mail: zhangwei8 More

Citation:
Qing Y, Li Q, Zhao LY, Shi P, Shan JL, Zhang W. LncRNA-PANDAR regulates the progression of thyroid carcinoma by targeting miR-637/KLK4. J Cancer 2021; 12(19):5879-5887. doi:10.7150/jca.55181. https://www.jcancer.org/v12p5879.htm
Other styles

File import instruction

Abstract

Graphic abstract

Thyroid gland carcinoma (TC) originates from follicular or parafollicular thyroid cells and is one of the most common endocrine organ malignancies. To explore the molecular mechanism by which long-chain non-coding RNAs regulate the growth and metastasis of thyroid gland carcinoma, in this study we focused on long non-coding RNAs (lncRNAs) that have been reported to be involved in tumorigenesis. We identified Promoter Region of CDKN 1A antisense DNA damage-activated RNA (PANDAR), which was positively correlated with thyroid gland carcinoma risk. PANDAR could promote thyroid gland carcinoma cell proliferation and metastasis. PANDAR negatively correlated with miR-637, and miR-637 overexpression suppressed thyroid gland carcinoma progression, which could be reversed by PANDAR. MiR-637 could target Kallikrein-related peptidases 4 (KLK4) to inhibit its expression, which was high in thyroid gland carcinoma. KLK4 inhibited cell progression in thyroid gland carcinoma cells. Knockdown of PANDAR expression inhibited cancer progression in nude mice. Overall, PANDAR can suppress miR-637 and induce KLK4 to regulate invasion and migration in thyroid gland carcinoma. Additionally, we identified miR-637 as a target of PANDAR in thyroid gland carcinoma, and PANDAR can be used as a novel therapeutic target for the treatment of thyroid gland carcinoma.

Keywords: Thyroid gland carcinoma, LncRNA PANDAR, MiR-637, KLK4, Progression

Citation styles

APA
Qing, Y., Li, Q., Zhao, L.Y., Shi, P., Shan, J.L., Zhang, W. (2021). LncRNA-PANDAR regulates the progression of thyroid carcinoma by targeting miR-637/KLK4. Journal of Cancer, 12(19), 5879-5887. https://doi.org/10.7150/jca.55181.

ACS
Qing, Y.; Li, Q.; Zhao, L.Y.; Shi, P.; Shan, J.L.; Zhang, W. LncRNA-PANDAR regulates the progression of thyroid carcinoma by targeting miR-637/KLK4. J. Cancer 2021, 12 (19), 5879-5887. DOI: 10.7150/jca.55181.

NLM
Qing Y, Li Q, Zhao LY, Shi P, Shan JL, Zhang W. LncRNA-PANDAR regulates the progression of thyroid carcinoma by targeting miR-637/KLK4. J Cancer 2021; 12(19):5879-5887. doi:10.7150/jca.55181. https://www.jcancer.org/v12p5879.htm

CSE
Qing Y, Li Q, Zhao LY, Shi P, Shan JL, Zhang W. 2021. LncRNA-PANDAR regulates the progression of thyroid carcinoma by targeting miR-637/KLK4. J Cancer. 12(19):5879-5887.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use